Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

130 questions · 149 findings · 10 reviews · ENT

No studies found 37 · 24.8%GRADE not reported 2 · 1.3%Very low 47 · 31.5%Low 36 · 24.2%Moderate 23 · 15.4%High 4 · 2.7%

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).

1 finding from 1 review

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat (longest… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review